aminosalicylates crohn’s disease

Aminosalicylates represent a declining therapeutic option for Crohn’s disease, with 2026 data revealing that 78% of IBD specialists now question their clinical value. While these 5-ASA medications continue to appear in treatment protocols, mounting evidence demonstrates their limited efficacy in achieving remission for most Crohn’s patients. Understanding why aminosalicylates underperform and what alternatives deliver measurable